

MIRA INFORM REPORT

Report No. :	520581
Report Date :	19.07.2018

IDENTIFICATION DETAILS

Name :	BBT BIOTECH GMBH
Registered Office :	Arnold-Sommerfeld-Ring 28, D 52499 Baesweiler
Country :	Germany
Date of Incorporation :	20.11.1998
Com. Reg. No.:	HRB 7464
Legal Form :	Private Limited Company
Line of Business :	<ul style="list-style-type: none"> • Manufacture of Pharmaceutical Preparations • Wholesale of Pharmaceutical, Medical and Orthpedic Goods
No. of Employees :	Not Available

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

MIRA's Rating :	A
-----------------	---

Credit Rating	Explanation	Rating Comments
A	Acceptable Risk	Business dealings permissible with moderate risk of default

Status :	Satisfactory
Payment Behaviour :	Slow but Correct
Litigation :	Clear

NOTES:

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating (31.12.2017)	Current Rating (01.04.2018)
Germany	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

GERMANY - ECONOMIC OVERVIEW

The German economy - the fifth largest economy in the world in PPP terms and Europe's largest - is a leading exporter of machinery, vehicles, chemicals, and household equipment and benefits from a highly skilled labor force. Like its Western European neighbors, Germany faces significant demographic challenges to sustained long-term growth. Low fertility rates and a large increase in net immigration are increasing pressure on the country's social welfare system and necessitate structural reforms.

Reforms launched by the government of Chancellor Gerhard SCHROEDER (1998-2005), deemed necessary to address chronically high unemployment and low average growth, contributed to strong economic growth and falling unemployment. These advances, as well as a government subsidized, reduced working hour scheme, help explain the relatively modest increase in unemployment during the 2008-09 recession - the deepest since World War II. The German Government introduced a minimum wage in 2015 that increased to \$9.79 (8.84 euros) in January 2017.

Stimulus and stabilization efforts initiated in 2008 and 2009 and tax cuts introduced in Chancellor Angela MERKEL's second term increased Germany's total budget deficit - including federal, state, and municipal - to 4.1% in 2010, but slower spending and higher tax revenues reduced the deficit to 0.8% in 2011 and in 2017 Germany reached a budget surplus of 0.7%. A constitutional amendment approved in 2009 limits the federal government to structural deficits of no more than 0.35% of GDP per annum as of 2016, though the target was already reached in 2012.

The German economy suffers from low levels of investment, and a government plan to invest 15 billion euros during 2016-18, largely in infrastructure, is intended to spur needed private investment. Following the March 2011 Fukushima nuclear disaster, Chancellor Angela MERKEL announced in May 2011 that eight of the country's 17 nuclear reactors would be shut down immediately and the remaining plants would close by 2022. Germany plans to replace nuclear power largely with renewable energy, which accounted for 29.5% of gross electricity consumption in 2016, up from 9% in 2000. Before the shutdown of the eight reactors, Germany relied on nuclear power for 23% of its electricity generating capacity and 46% of its base-load electricity production. Domestic consumption, investment, and exports are likely to drive German GDP growth in 2018, and the country's budget and trade surpluses are likely to remain high.

Source : CIA

COMPANY NAME AND ADDRESS

BBT BIOTECH GMBH

Company Status: Active
Arnold-Sommerfeld-Ring 28
D 52499 Baesweiler
Telephone: 02401/933100
Telefax: 02401/9331090
Homepage: www.bbt-biotech.de
E-mail: office@bbt-biotech.de

VAT NO.

DE812638360

COMPANY SUMMARY

LEGAL FORM: Private limited company
Date of foundation: 20.11.1998
Shareholders'
agreement: 20.11.1998
Registered on: 01.12.1998
Commercial Register: Local court 52070 Aachen
under: HRB 7464

SHARE CAPITAL

EUR 1,533,875.64

Shareholder:

Pharma-Zentrale GmbH
Loerfeldstr. 20
D 58313 Herdecke
Post Box:
13 55, D 58303 Herdecke
Legal form: Private limited company
Share capital: EUR 3,000,000.00
Share: EUR 1,533,875.64
Registered on: 13.01.1953
Reg. data: 58097 Hagen, HRB 5005

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Control and profit transfer agreement

Manager: Jürgen Kirstein
D 58239 Schwerte
born: 01.01.1958
Profession: Businessman

Manager: Detlef Gopon
D 45549 Sprockhövel
born: 19.06.1955
Profession: Businessman

Proxy: Dr. Rainer Rudolf Rogasch
D 34513 Waldeck
authorized to jointly represent the company
born: 26.07.1960
Profession: Pharmacist
Marital status: unknown

Proxy: Dr. Roland Gande
D 41538 Dormagen
authorized to jointly represent the company
born: 25.01.1977

Proxy: Dirk Thoma
D 52531 Übach-Palenberg
authorized to jointly represent the company
born: 18.03.1968

Further functions/participations of Jürgen Kirstein (Manager)

Manager: Polamin-Werk GmbH
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 33,745.26
Registered
on: 23.09.1992
Reg. data: 58097 Hagen, HRB 5197

Manager: Dr. Poehlmann & Co. Gesellschaft mit
beschränkter Haftung
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 25,564.59
Registered
on: 08.05.1967
Reg. data: 58097 Hagen, HRB 5001

Manager:

Pharma-Zentrale GmbH
Loerfeldstr. 20
D 58313 Herdecke
Post Box:
13 55, D 58303 Herdecke
Legal form: Private limited company
Share capital: EUR 3,000,000.00
Registered
on: 13.01.1953
Reg. data: 58097 Hagen, HRB 5005

Manager:

Ardeypharm GmbH Pharmazeutische Fabrik
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 25,564.59
Registered
on: 09.01.1970
Reg. data: 58097 Hagen, HRB 5012

Manager:

Dr. Ponsold Pharma GmbH
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 26,000.00
Registered
on: 20.01.1976
Reg. data: 58097 Hagen, HRB 5020

Manager:

Sanoreform Gesellschaft mit beschränkter
Haftung, Naturheilmittel, Diätprodukte,
biologische Kosmetik
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 25,000.00
Registered
on: 28.07.1994
Reg. data: 58097 Hagen, HRB 5196

Further functions/participations of Detlef Gopon (Manager)

Manager:

Polamin-Werk GmbH
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 33,745.26
Registered

on: 23.09.1992
Reg. data: 58097 Hagen, HRB 5197
Manager: Dr. Poehlmann & Co. Gesellschaft mit
beschränkter Haftung
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 25,564.59
Registered
on: 08.05.1967
Reg. data: 58097 Hagen, HRB 5001
Manager: Pharma-Zentrale GmbH
Loerfeldstr. 20
D 58313 Herdecke
Post Box:
13 55, D 58303 Herdecke
Legal form: Private limited company
Share capital: EUR 3,000,000.00
Registered
on: 13.01.1953
Reg. data: 58097 Hagen, HRB 5005
Manager: Ardeypharm GmbH Pharmazeutische Fabrik
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 25,564.59
Registered
on: 09.01.1970
Reg. data: 58097 Hagen, HRB 5012
Manager: Dr. Ponsold Pharma GmbH
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 26,000.00
Registered
on: 20.01.1976
Reg. data: 58097 Hagen, HRB 5020
Manager: Sanoreform Gesellschaft mit beschränkter
Haftung, Naturheilmittel, Diätprodukte,
biologische Kosmetik
Loerfeldstr. 20
D 58313 Herdecke
Legal form: Private limited company
Share capital: EUR 25,000.00

Registered
on: 28.07.1994
Reg. data: 58097 Hagen, HRB 5196

RESIGNED ACTING PERSONS AND SHAREHOLDERS

30.08.2004 - 19.10.2017 Manager
Jürgen Malinka
D 59379 Selm

BUSINESS ACTIVITIES

Main industrial sector

21200 Manufacture of pharmaceutical preparations
4646 Wholesale of pharmaceutical, medical and orthopedic goods

FINANCIAL INFORMATION

Payment experience: within agreed terms

Negative information: We have no negative information at hand.

REAL ESTATE

Type of ownership: Tenant
Address: Arnold-Sommerfeld-Ring 28
D 52499 Baesweiler

Land register documents were not available.

BANKERS

SPARKASSE AACHEN, 52499 BAESWEILER
Sort. code: 39050000
BIC: AACSD33XXX

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

FINANCIAL FIGURES

Financial year: 01.01. - 31.12.
Share capital: EUR 1,533,875.64

The number of employees is not known.

Control and profit transfer agreement to:
Pharma-Zentrale GmbH
Loerfeldstr. 20
D 58313 Herdecke
Post Box:
13 55, D 58303 Herdecke

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 68.57
UK Pound	1	INR 89.73
Euro	1	INR 79.74
EUR	1	INR 80.19

Note: Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	PRI
Report Prepared by :	NIT

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)